Syndax Reports First Quarter 2026 Financial Results and Provides Business Update

Syndax Reports Strong Q1 2026 Revenue and Key Pipeline Milestones

Syndax Pharmaceuticals reported strong financial results for Q1 2026, with total revenue reaching $64.9 million, a 224% year-over-year increase. Revuforj net revenue was $48.9 million, driven by increased uptake in relapsed or refractory NPM1 mutated acute myeloid leukemia, while Niktimvo collaboration revenue was $15.9 million from $55.1 million in net sales. The company anticipates multiple key data readouts in 2026 for both drugs, including real-world and post-HSCT maintenance data for revumenib, and topline Phase 2 data for axatilimab in idiopathic pulmonary fibrosis and newly diagnosed chronic GVHD. Syndax aims for continued commercial growth and profitability.

• Robust Financial Performance: Syndax achieved a total revenue of $64.9 million in Q1 2026, marking a significant 224% year-over-year increase. This was fueled by $48.9 million in Revuforj net revenue, a 144% increase from Q1 2025, and $15.9 million in Niktimvo collaboration revenue. The company reported a net loss of $42.7 million, a substantial improvement from $84.8 million in the prior year, and ended the quarter with $352.1 million in cash, cash equivalents, and short-term investments.
• Revuforj's Expanding Market Presence and Pipeline Progress: Revuforj demonstrated strong commercial uptake, particularly in relapsed or refractory NPM1 mutated acute myeloid leukemia, with total prescriptions increasing by approximately 160% year-over-year. A recent analysis highlighted that nearly half of R/R KMT2A translocated patients are proceeding to hematopoietic stem cell transplant after Revuforj treatment, which is expected to extend treatment duration. The company anticipates new real-world, frontline, and post-HSCT maintenance data for revumenib in Q2 2026, alongside progress in pivotal Phase 3 trials like EVOLVE-2 and REVEAL-ND.
• Niktimvo's Commercial Growth and Upcoming Clinical Milestones: Niktimvo generated $55.1 million in net revenue, contributing $15.9 million in collaboration revenue to Syndax, reflecting strong growth since its launch. Data from nine axatilimab abstracts, including an oral presentation, were shared at the Tandem Meetings in February 2026, showcasing clinical responses in chronic GVHD-related bronchiolitis obliterans syndrome. Topline data from Phase 2 trials of axatilimab in idiopathic pulmonary fibrosis (MAXPIRe) and newly diagnosed chronic GVHD (in combination with ruxolitinib) are expected in Q4 2026, with a pivotal Phase 3 trial in chronic GVHD also underway.

The Persistent Challenges in KMT2Ar Acute Leukemia Treatment

KMT2A-rearranged acute leukemia presents formidable treatment challenges despite recent therapeutic advances. Current approaches are limited by inherent disease aggressiveness, high treatment failure rates, and complex resistance mechanisms. These obstacles necessitate continued innovation in therapeutic strategies and patient management approaches.

• Chemotherapy resistance and treatment failure: Current chemotherapy fails in >50% of patients with KMT2A-rearranged acute lymphoblastic leukemia, with limited responses to contemporary chemotherapeutic treatments and hematopoietic stem cell transplantations (HSCT)

• Aggressive disease characteristics: KMT2A-rearranged leukemia exhibits rapid onset, aggressive progression, and significantly worse prognosis compared to non-KMT2A-rearranged leukemias

• Early mortality and bleeding complications: 60-day mortality in KMT2A-rearranged AML patients was 15% compared with 7% in normal karyotype cases, with significantly higher occurrence of major bleeding events and disseminated intravascular coagulopathy

• Rapid resistance development to novel therapies: Early resistance emergence to menin inhibitors occurs primarily through MEN1 mutations, observed as early as two treatment cycles across clinical trials

• Immunotherapy target identification challenges: Patient-specific blast immunophenotypes and their changes during disease progression complicate immunotherapy approaches, with KMT2A-rearranged patients showing more profound immunophenotypic changes at relapse

• CAR T-cell therapy limitations: Relapse due to target antigen loss or downregulation has emerged as a major clinical dilemma in CAR T-cell immunotherapies targeting CD19 or CD22

• Incomplete understanding of molecular heterogeneity: The numerous fusion partners result in an incompletely understood mutational landscape and prognostic impact of specific 11q23/KMT2A rearrangements

• Age-related poor outcomes: Older patients (≥60 years) with KMT2A rearrangements demonstrate particularly poor outcomes comparable to adverse-risk group patients

• Treatment intensity limitations: Patients treated with low-intensity treatment achieve only 7% five-year overall survival compared to 66% with intensive chemotherapy, limiting options for patients unable to tolerate aggressive approaches

Mapping Revuforj's Clinical Trials Across Acute Leukemia

The AUGMENT-101 trial represents the pivotal study for revumenib in KMT2A-rearranged acute leukemia, demonstrating meaningful clinical activity in heavily pretreated patients. This Phase I/II study established the foundation for FDA approval in November 2024, with additional menin inhibitors showing promise in ongoing trials.

Revuforj's Reported Outcomes and Future Growth Trajectory

Revumenib (SNDX-5613), a potent and selective oral inhibitor of the menin-KMT2A interaction, received FDA approval in November 2024 following demonstration of clinical efficacy in relapsed or refractory KMT2A-rearranged acute leukemia. In the first-in-human phase 1 clinical trial, revumenib achieved a 30% rate of complete remission or complete remission with partial hematologic recovery (CR/CRh) in the efficacy analysis population. Notably, remissions occurred in leukemias refractory to multiple previous lines of therapy, with demonstrated clearance of residual disease using sensitive clinical assays and hallmarks of differentiation into normal hematopoietic cells, including differentiation syndrome. Across five pivotal trials, revumenib demonstrated consistent efficacy with MRD-negative rates of 70-90% in both KMT2A-rearranged and NPM1-mutated leukemias.

The safety profile of revumenib was generally manageable, with a low frequency of grade 3 or higher treatment-related adverse events. Asymptomatic prolongation of the QT interval on electrocardiography was identified as the only dose-limiting toxicity. However, early resistance emergence, primarily through MEN1 mutations, was observed across trials, with resistance developing as early as two treatment cycles. Other menin inhibitors in development have shown varying efficacy profiles, with ziftomenib demonstrating particular efficacy in NPM1-mutated cases but a higher incidence of differentiation syndrome (30%) in KMT2A-rearranged patients, while bleximenib reported a 93% overall response rate pending MRD validation.

For patients with concurrent FLT3 mutations and KMT2A rearrangements treated with gilteritinib, outcomes remain challenging. In a real-world cohort of 152 patients receiving single-agent gilteritinib across 38 UK hospitals, complete remission was achieved in 21% and CR with incomplete recovery in an additional 9%, with median overall survival of 9.5 months. Multivariable analysis demonstrated that KMT2A rearrangement was associated with worse survival outcomes. These findings underscore the continued poor prognosis associated with KMT2A rearrangements, which occur in up to 10% of acute leukemias and account for 75-80% of leukemia cases in infants under one year of age.

Syndax's Dual Engine: Driving Growth with Targeted Therapies

Syndax Pharmaceuticals' impressive financial results for Q1 2026 highlight the successful commercialization of its two recently approved targeted therapies, Revuforj (revumenib) and Niktimvo (axatilimab). This performance underscores the growing impact of precision medicine in addressing critical unmet needs in oncology and rare diseases.

Revuforj, a menin inhibitor, has rapidly gained traction in the challenging landscape of relapsed or refractory acute myeloid leukemia (AML) with KMT2A rearrangement or NPM1 mutation. These are aggressive subtypes where treatment options have historically been limited and outcomes poor. The drug's strong revenue generation reflects its ability to provide meaningful responses in a heavily pre-treated population. Looking ahead, upcoming data on real-world use and post-hematopoietic stem cell transplantation (HSCT) maintenance could significantly expand Revuforj's utility, potentially moving it into earlier lines of therapy or as a maintenance strategy to prevent relapse. However, the emergence of resistance mutations, such as MEN1 mutations, and the presence of TP53 mutations conferring de novo resistance, remain key considerations for long-term efficacy, necessitating ongoing research into optimal combination strategies.

Similarly, Niktimvo, an anti-CSF1R antibody, has demonstrated its value in recurrent or refractory chronic graft-versus-host disease (cGVHD), a debilitating complication of allogeneic HSCT. Its approval has provided a much-needed option for patients who have failed multiple prior lines of systemic therapy. The strategic implications for Niktimvo are substantial, with Phase 2 data anticipated in newly diagnosed cGVHD and idiopathic pulmonary fibrosis (IPF). Success in these indications would not only broaden its market significantly but also establish its role in earlier treatment paradigms for cGVHD and open an entirely new therapeutic area in IPF. While effective, the competitive landscape in cGVHD, with other approved agents like ruxolitinib and belumosudil, and the need to manage dose-dependent adverse events, will be crucial for its sustained success.

Overall, Syndax is leveraging its innovative pipeline to address high-unmet-need conditions. The company's ability to translate scientific breakthroughs into commercial success, coupled with a robust pipeline of data readouts, positions it as a significant player in specialized therapeutic markets. The strategic focus on expanding the utility of these assets through new indications and combination therapies will be vital for sustained growth and competitive advantage.